HK1205146A1 - 藥物製劑 - Google Patents

藥物製劑

Info

Publication number
HK1205146A1
HK1205146A1 HK15105706.7A HK15105706A HK1205146A1 HK 1205146 A1 HK1205146 A1 HK 1205146A1 HK 15105706 A HK15105706 A HK 15105706A HK 1205146 A1 HK1205146 A1 HK 1205146A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
HK15105706.7A
Other languages
English (en)
Inventor
．亞特斯
．克利普斯通
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of HK1205146A1 publication Critical patent/HK1205146A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK15105706.7A 2012-06-21 2015-06-16 藥物製劑 HK1205146A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21
PCT/EP2013/062898 WO2013190047A1 (en) 2012-06-21 2013-06-20 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
HK1205146A1 true HK1205146A1 (zh) 2015-12-11

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105706.7A HK1205146A1 (zh) 2012-06-21 2015-06-16 藥物製劑

Country Status (25)

Country Link
US (1) US20150150979A1 (zh)
EP (1) EP2864356A1 (zh)
JP (1) JP6157611B2 (zh)
KR (1) KR20150032941A (zh)
CN (1) CN104520326A (zh)
AR (1) AR091530A1 (zh)
AU (1) AU2013279347A1 (zh)
BR (1) BR112014031841A2 (zh)
CA (1) CA2876012A1 (zh)
CL (1) CL2014003283A1 (zh)
CO (1) CO7170174A2 (zh)
EA (1) EA201590061A1 (zh)
EC (1) ECSP15002095A (zh)
HK (1) HK1205146A1 (zh)
IL (1) IL235921A0 (zh)
MA (1) MA37777B1 (zh)
MX (1) MX2014014717A (zh)
NZ (1) NZ702342A (zh)
PE (1) PE20150190A1 (zh)
PH (1) PH12014502596A1 (zh)
SG (1) SG11201407779YA (zh)
TN (1) TN2014000498A1 (zh)
TW (1) TW201406398A (zh)
WO (1) WO2013190047A1 (zh)
ZA (1) ZA201409020B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923844C (en) 2013-09-11 2022-07-26 Arsia Therapeutics, Inc. Liquid protein formulations containing organophosphates
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CA3109613A1 (en) 2016-05-28 2017-12-07 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Bio-Technology, Government Of India Uttroside b and derivatives thereof as therapeutics for hepatocellular carcinoma
CN110062620B (zh) * 2016-10-31 2023-12-05 德国费森尤斯卡比有限公司 液体药物组合物
AU2018207367B2 (en) 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20230405018A1 (en) * 2020-11-18 2023-12-21 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
SI2335725T1 (sl) * 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2011143307A1 (en) * 2010-05-14 2011-11-17 Amgen Inc. High concentration antibody formulations
CN103108658B (zh) * 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
CN103582724A (zh) * 2011-04-07 2014-02-12 葛兰素史密斯克莱有限责任公司 粘度降低的制剂
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Also Published As

Publication number Publication date
JP6157611B2 (ja) 2017-07-05
CA2876012A1 (en) 2013-12-27
AU2013279347A1 (en) 2014-12-18
IL235921A0 (en) 2015-01-29
NZ702342A (en) 2016-07-29
CO7170174A2 (es) 2015-01-28
AR091530A1 (es) 2015-02-11
EA201590061A1 (ru) 2015-05-29
MX2014014717A (es) 2015-03-06
CN104520326A (zh) 2015-04-15
TW201406398A (zh) 2014-02-16
BR112014031841A2 (pt) 2017-06-27
US20150150979A1 (en) 2015-06-04
KR20150032941A (ko) 2015-03-31
SG11201407779YA (en) 2015-02-27
JP2015520206A (ja) 2015-07-16
ECSP15002095A (es) 2015-11-30
CL2014003283A1 (es) 2016-04-01
MA37777B1 (fr) 2017-07-31
TN2014000498A1 (en) 2016-03-30
WO2013190047A1 (en) 2013-12-27
EP2864356A1 (en) 2015-04-29
ZA201409020B (en) 2016-09-28
PH12014502596A1 (en) 2015-01-12
PE20150190A1 (es) 2015-02-13
MA20150436A1 (fr) 2015-11-30

Similar Documents

Publication Publication Date Title
HK1209638A1 (zh) 藥物組合物
HK1203812A1 (zh) 新型藥物製劑
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1205146A1 (zh) 藥物製劑
AP2015008208A0 (en) Pharmaceutical administration forms comprising
HK1205683A1 (zh) 穩定性提高的藥物製劑
LT2934544T (lt) Farmacinė kompozicija, apimanti ciklezonidą
HK1215789A1 (zh) 藥物組合
EP2934542A4 (en) PHARMACEUTICAL COMPOUNDS
HK1206269A1 (zh) 包含苯達莫司汀的藥物製劑
HK1207296A1 (zh) 基於基因型或表型的藥物製劑
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
SG11201406097SA (en) Capsule formulation
GB201211153D0 (en) Pharmaceutical compositions
GB201202027D0 (en) Pharmaceutical compounds
HK1209339A1 (zh) 藥物配方
HK1204945A1 (zh) 含有氟吡汀的藥物製劑
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL238075A0 (en) pharmaceutical preparations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions